Concepedia

Alicia Michaud

AM

6

Publications

375

Citations

6

H-Index

2018

Active since

Affiliations

Selecta Biosciences (United States)(Current)

Alicia Michaud is an author at Selecta Biosciences (United States) specializing in cell transplantation, inflammation, and t cell immunity.

ORCID

Top concepts

Publications per year

2018–2023

6

Publications

6

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

Amine Meliani, Florence Boisgérault, Romain Hardet et al. · Nature Communications · 2018 · 241 citations · Full text

Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles

Petr O. Ilyinskii, Alicia Michaud, Christopher Roy et al. · Science Advances · 2021 · 48 citations · Full text

ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia

Petr O. Ilyinskii, Alicia Michaud, Gina L. Rizzo et al. · Molecular Therapy — Methods & Clinical Development · 2021 · 34 citations · Full text

Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy

Petr O. Ilyinskii, Conlin P. O’Neil, Chad J. Roy et al. · PLoS ONE · 2018 · 20 citations · Full text

Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease

Takashi Kishimoto, Max Fournier, Alicia Michaud et al. · Journal of Autoimmunity · 2023 · 19 citations · Full text

, , +16

Rows per page

1–5 of 6